While short-term momentum indicators like MACD and RSI are flashing bearish, the macro-structure for TSLA is coiled for a move higher. We are seeing a convergence of low implied volatility and a high Max Pain point at 400, which often acts as a target for options expiration. Analyst targets provide a fundamental floor for the bullish thesis, suggesting a delta of 15% upside. The lack of immediate catalyst noise allows the stock to trade toward its technical targets without external shocks. We are betting on a mean reversion toward the analyst target and options max pain.

Stop: $325.59 · T1: $409.14 · R:R 1.5

TSLA is currently in a neutral-to-bullish transition phase where technicals are aligning despite lingering bearish sentiment. With a bullish MACD and price holding above key support at 363.37, the setup favors an upside move. The most compelling factor is the low IV Rank, which makes call options an inexpensive bet on a volatility expansion. Max Pain at 400 acts as a magnet for price action over the next week. While confidence is low, the risk-to-reward profile is too attractive to ignore.

Stop: $363.37 · T1: $406.7 · R:R 8.01

TSLA is currently in a consolidation phase with neutral trend and pattern data, but the underlying momentum is shifting bullish via the MACD. We are seeing a massive disconnect between the current price and the Max Pain level of 400, which historically pulls price upward. With IV Rank at a basement level of 12, options are priced for a snooze-fest, providing a high-convexity entry for bulls. Analyst targets further support a move toward the 380-390 range. This is a classic 'buy the lull' play before a momentum expansion.

Stop: $297.86 · T1: $371.96 · R:R 1.5

TSLA is currently trapped in a neutral trend but is showing classic signs of a bottoming process. With RSI hitting oversold levels and price holding the 297.38 support line, the risk-to-reward profile for a long position is highly attractive. Despite the bearish MACD, the massive gap between the current price and analyst targets creates a compelling 'spring' effect. We are playing a mean-reversion bounce that aligns with long-term institutional targets. This is a high-conviction tactical play on a short-term recovery.

Stop: $297.38 · T1: $360.04 · R:R 4.15

TSLA is currently in a momentum lull, but the underlying data points to a bullish reversal. While L4 momentum is bearish, it's countered by a 'somewhat bullish' sentiment and a clear analyst target of $425. The most compelling factor is the IV Rank of 13, meaning the market is not pricing in a big move, creating a 'cheap' entry for options. With Max Pain at $400, there is a strong probabilistic pull toward that level over the next week. We are buying the momentum dip to ride the wave toward the $412-$429 resistance zone.

Stop: $340.69 · T1: $412.96 · R:R 2

TSLA is currently adrift without a strong trend, but the underlying momentum is decaying. With the MACD bearish and RSI sliding toward 40, the path of least resistance is down. The critical factor is the 3-day countdown to earnings, which typically triggers volatility and risk-off behavior in high-beta names. Given the lack of nearby support and the distance to resistance, a corrective move toward the $330 range is probable. We are playing the convergence of bearish momentum and catalyst-driven instability.

Stop: $414.66 · T1: $338.7 · R:R 1.25

TSLA is currently in a momentum-driven window where the technicals are quietly aligning. While the trend layers are neutral, the bullish MACD and RSI indicate a positive drift toward the 497 resistance level. With IV Rank at 12, the cost of entry for options is a steal, allowing us to speculate on a move higher without paying a volatility premium. We are essentially betting on the current momentum to bridge the gap between the current price and the analyst target. If the 400 max pain level doesn't drag the price down, the trajectory remains aggressively upward.

Stop: $390.3 · T1: $479.35 · R:R 1.5